Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD – Get Free Report) Director Julie Mchugh sold 21,571 shares of the firm’s stock in a transaction that occurred on Tuesday, June 16th. The shares were sold at an average price of $3.73, for a total transaction of $80,459.83. Following the completion of the transaction, the director owned 250,749 shares of the company’s stock, valued at $935,293.77. This trade represents a 7.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.
Ironwood Pharmaceuticals Price Performance
NASDAQ IRWD opened at $3.54 on Friday. The company has a market capitalization of $577.23 million, a price-to-earnings ratio of 5.90 and a beta of 0.25. Ironwood Pharmaceuticals, Inc. has a twelve month low of $0.66 and a twelve month high of $5.78. The stock’s 50-day simple moving average is $3.83 and its two-hundred day simple moving average is $3.88.
Ironwood Pharmaceuticals (NASDAQ:IRWD – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.24 EPS for the quarter, missing analysts’ consensus estimates of $0.25 by ($0.01). Ironwood Pharmaceuticals had a net margin of 28.26% and a negative return on equity of 39.65%. The firm had revenue of $106.51 million for the quarter, compared to the consensus estimate of $92.11 million. On average, equities analysts expect that Ironwood Pharmaceuticals, Inc. will post 1.04 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several research analysts have recently commented on IRWD shares. Wall Street Zen raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Sunday, May 17th. Citizens Jmp raised their target price on shares of Ironwood Pharmaceuticals from $8.00 to $10.00 and gave the stock a “market outperform” rating in a report on Thursday, February 26th. Jefferies Financial Group reissued a “hold” rating and set a $3.70 target price on shares of Ironwood Pharmaceuticals in a research note on Thursday, February 26th. Zacks Research downgraded Ironwood Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, February 25th. Finally, Weiss Ratings reissued a “sell (d+)” rating on shares of Ironwood Pharmaceuticals in a research report on Monday, April 27th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $6.23.
Check Out Our Latest Analysis on Ironwood Pharmaceuticals
Ironwood Pharmaceuticals Company Profile
Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.
Featured Stories
- Five stocks we like better than Ironwood Pharmaceuticals
- Aehr Spikes on New Order, But Has Stock Gotten Ahead of Itself?
- Rackspace’s AI Land Grab: Plugging Into the Next Compute Boom
- Satellogic Is Tiny But Its Revenue Growth Is Hard to Ignore
- Why Kroger’s Pullback Could Be a Gift for Patient Investors
Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
